⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

October 14, 2016Expert Review of Anticancer TherapyOpen Access

Optimal design and endpoint of clinical trials using immune checkpoint blocking agents

Bhumsuk Keam Hun Jung Byung Ho Nam

View Full Paper

Ask AI

Bookmark

Share

Abstract

Immune checkpoint blocking agents (ICBAs) that target either programmed cell death 1 (PD-1) programmed cell death ligand 1 (PD-L1), or cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) have show...

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Keam et al. (2016) studied this question.

synapsesocial.com/papers/6a70648f35aa2c282ce1b4dd https://doi.org/10.1080/14737140.2016.1248945

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Improved Survival with Ipilimumab in Patients with Metastatic MelanomaRCT · 2010 · 15,158 citations
2Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung CancerOriginal Research · 2015 · 9,333 citations
3Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung CancerOriginal Research · 2015 · 8,446 citations
4Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response CriteriaRCT · 2009 · 3,223 citations
5Nivolumab versus Everolimus in Advanced Renal-Cell CarcinomaOriginal Research · 2015 · 5,800 citations

More related papers

Statistical issues and challenges in immuno-oncology2013

More from Expert Review of Anticancer Therapy

Apalutamide in prostate cancer: clinical evidence, disease modification hypothesis, and emerging treatment de‑intensification strategiesThu,
How zongertinib was developed for HER2-mutant non-small cell lung cancer: a plain language summarySun,
Targeting KIT and PDGFRA mutations in advanced gist: current and future clinical implicationsSat,
Myelodysplastic syndromes/neoplasms presenting with isolated thrombocytopenia: a poorly understood pathophysiology, difficult to diagnose, and challenging to treat entityThu,